Alterity Therapeutics Ltd. (ASX:ATH) has featured among the ASX's decliners in September 2026, a familiar pattern for a clinical-stage biotechnology stock whose share price tends to swing on trial milestones and market sentiment rather than earnings. The Melbourne-based drug developer is best known for ATH434, its lead candidate for Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disease. With no marketed products, Alterity remains a high-risk, high-reward proposition, and its ASX shares can move sharply in both directions as investors weigh clinical progress against the long road to commercialisation.

Latest Developments

Alterity has continued to advance ATH434 through late 2025 and into 2026. The company reported positive results from its ATH434-202 Phase 2 trial in MSA, and in March 2026 said it received positive feedback from the US Food and Drug Administration following a Type C meeting on the Phase 3 program. ATH434 is designed to inhibit the aggregation of alpha-synuclein by targeting excess iron in the brain, a mechanism the company argues is well suited to MSA. Alterity, which is also listed on the Nasdaq under the ticker ATHE, has maintained an active investor-outreach schedule, including participation in the Canaccord Genuity Growth Conference in August 2026 and a fireside chat at the Cantor Global Healthcare Conference in early September 2026.

What Could Come Next

The key catalyst is the design and eventual commencement of the ATH434 Phase 3 study in MSA. Further detail on trial protocol, funding arrangements and partnering discussions could all influence the ASX stock. Continued conference presentations and any peer-reviewed publication of the Phase 2 data may also shape investor expectations through the remainder of 2026.

Risks to Watch

Clinical-stage biotech carries substantial risk. Phase 3 trials are expensive, lengthy and can Fail even after encouraging earlier data. Alterity will likely require additional capital, which could dilute existing shareholders. Regulatory timelines can slip, and MSA's complexity makes efficacy hard to demonstrate. As a stock with no commercial revenue, ATH is inherently volatile and sensitive to sentiment shifts.

Conclusion

Alterity Therapeutics remains a story defined by its ATH434 program and the promise it holds for MSA patients. Recent regulatory engagement and Phase 2 results have kept the company relevant, but the path to a marketed product is long and uncertain. As 2026 progresses, the focus for ASX investors will be on how Alterity translates encouraging early data and FDA dialogue into a funded, well-designed Phase 3 trial.